DXS International's EBIT per Share for the
six
months ended in Apr. 2025 was €-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Apr. 2025 was €-0.00.
During the past 3 years, the average EBIT per Share Growth Rate was -26.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for DXS International's EBIT per Share or its related term are showing as below:
STU:7EE'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -26 Med: 2.35 Max: 30.7
Current: -26
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of DXS International was 30.70% per year. The lowest was -26.00% per year. And the median was 2.35% per year.
STU:7EE's 3-Year EBIT Growth Rate is ranked worse than 90.32% of 527
companies
in the Healthcare Providers & Services industry
Industry Median: 12.1
vs STU:7EE: -26.00
DXS International (STU:7EE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
DXS International EBIT per Share Related Terms
DXS International EBIT per Share Historical Data
* Premium members only.
The historical data trend for DXS International's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT per Share for the trailing twelve months (TTM) ended in Apr. 2025 was €-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DXS International (STU:7EE) has a EBIT per Share of €-0.00 as of Apr. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on DXS International and its competitors. According to the industry distribution chart, DXS International ranks #476 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 90.3%.
Is DXS International's EBIT per Share too high?
DXS International's current EBIT per Share is €-0.00. Based on the distribution chart, DXS International ranks #476 out of 527 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, DXS International has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does DXS International's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DXS International ranks #476 out of 527 companies for EBIT per Share. This places DXS International in the lower half of its industry. The industry median EBIT per Share is 12.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.10, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on DXS International and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DXS International's current EBIT per Share is €-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
DXS International (STU:7EE) has a current EBIT per Share of €-0.00. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 45% below its estimated fair value. The current EBIT per Share is €-0.00. DXS International's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For DXS International (STU:7EE), the current EBIT per Share is €-0.00 as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DXS International (STU:7EE) Overvalued in 2026?
Based on GuruFocus' analysis, DXS International stock appears to be undervalued.
The current stock price of €0.01 is trading 45% below its estimated GF Value™ of €0.02.
Key valuation signals for STU:7EE:
EBIT per Share: €-0.00
GF Value™: €0.02 vs. price of €0.01 (45% below fair value)
No single metric tells the full story. See the STU:7EE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.
39GF Score
Get the complete analysis for STU:7EE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7EE has been successfully added to your 
